KYNTRA BIO, INC.
KYNBNasdaq
$7.23
↓ -2.2%Jul 17 close · end-of-day
Price
1Y↓ -3.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$29.3M
Enterprise Value
-$58.0M
P/E
0.2
P/S
3.9
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-73.1%
Dividend Yield
—
Revenue (TTM)
$7.4M
Net Income (TTM)
$163.6M
Free Cash Flow (TTM)
-$21.4M
Gross Margin
—
Operating Margin
-602.1%
Net Margin
2199.4%
ROE
-373.5%
ROIC
—
Debt / Equity
—
Net Cash
$87.2M
Return 1Y
-10.4%
Company profile
FibroGen, Inc. discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan. Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor, is in Phase III.
- CEO
- Enrique A. Conterno
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 570
- Headquarters
- California
- Website
- fibrogen.com
Management & directors
- Delucia DavidChief Financial Officer
- Wettig ThaneCEO
Roles derived from SEC Form 4 filings.
Earnings
KYNB Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$3.7M↑ +36.5%
Diluted EPS-$3.76↓ -427.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $176.3M | $235.3M | $140.7M | $46.8M | $29.6M | $6.4M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$191.9M | -$288.5M | -$301.0M | -$322.7M | -$150.4M | -$45.9M |
| Net income | -$189.3M | -$290.0M | -$293.7M | -$284.2M | -$47.6M | $183.5M |
| Diluted EPS | -$2.11 | -$3.14 | -$3.14 | -$2.92 | -$11.89 | $45.37 |
| Operating cash flow | $81.6M | -$82.2M | -$145.9M | -$315.0M | -$138.0M | -$4.8M |
| Free cash flow | $77.6M | -$87.4M | -$149.7M | -$317.5M | -$138.3M | -$4.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -108.8% | -122.6% | -213.9% | -689.5% | -507.8% | -712.7% |
| Net margin | -107.4% | -123.3% | -208.7% | -607.3% | -160.6% | 2848.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $998,000.00 | $123,000.00 | $3.1M | $2.7M | $1.3M | $1.1M | $1.3M | $3.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$46.4M | -$47.7M | -$7.1M | -$14.9M | -$12.1M | -$5.4M | -$13.5M | -$13.8M |
| Net income | -$15.5M | -$17.1M | $18.0M | $4.6M | -$7.6M | $200.6M | -$14.2M | -$15.2M |
| Diluted EPS | -$3.89 | -$4.25 | -$3.42 | $1.15 | -$1.88 | $49.61 | -$3.51 | -$3.76 |
| Operating cash flow | -$39.9M | -$8.4M | -$30.5M | $2.7M | $12.7M | -$1.8M | -$18.3M | -$13.9M |
| Free cash flow | -$39.9M | -$8.5M | -$30.6M | $2.7M | $12.7M | -$1.9M | -$18.3M | -$13.9M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -4650.1% | -38774.0% | -227.5% | -544.7% | -894.1% | -502.9% | -1058.1% | -369.7% |
| Net margin | -1557.5% | -13889.4% | 573.4% | 169.4% | -564.0% | 18646.5% | -1113.5% | -406.6% |
Company news
May 11, 2026
May 7, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-06 | Wettig Thane· CEO | Tax withholding | 198 | $6.71 | $1,328.58 | filing |
| 2026-06-06 | DeLucia David· Chief Financial Officer | Tax withholding | 52 | $6.71 | $348.92 | filing |
| 2026-05-14 | Wettig Thane· CEO | Buy | 2,800 | $7.09 | $19,852.00 | filing |
| 2026-05-14 | Wettig Thane· CEO | Buy | 2,800 | $7.09 | $19,852.00 | filing |
| 2026-03-06 | Wettig Thane· CEO | Tax withholding | 277 | $6.84 | $1,894.68 | filing |
| 2026-03-06 | DeLucia David· Chief Financial Officer | Tax withholding | 60 | $6.84 | $410.40 | filing |
| 2025-12-06 | Wettig Thane· CEO | Tax withholding | 259 | $8.42 | $2,180.78 | filing |
| 2025-12-06 | DeLucia David· Chief Financial Officer | Tax withholding | 52 | $8.42 | $437.84 | filing |
| 2025-11-17 | Wettig Thane· CEO | Buy | 2,700 | $9.10 | $24,569.73 | filing |
| 2025-11-13 | Wettig Thane· CEO | Buy | 1,000 | $9.18 | $9,180.00 | filing |
| 2025-09-06 | Wettig Thane· CEO | Tax withholding | 248 | $12.10 | $3,000.80 | filing |
| 2025-09-06 | DeLucia David· Chief Financial Officer | Tax withholding | 53 | $12.10 | $641.30 | filing |
| 2025-06-30 | Schoeneck James A | Buy | 23,567 | $5.07 | $119,484.69 | filing |
Latest 13 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.